|
US3707475A
(en)
|
1970-11-16 |
1972-12-26 |
Pfizer |
Antiinflammatory imidazoles
|
|
DE3029376A1
(de)
|
1980-07-31 |
1982-03-18 |
Nepera Chemical Co. Inc., Harriman, N.Y. |
Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
|
|
DE3486009T2
(de)
|
1983-09-09 |
1993-04-15 |
Takeda Chemical Industries Ltd |
5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
|
|
JP2722586B2
(ja)
|
1989-01-13 |
1998-03-04 |
大正製薬株式会社 |
インドリルイミダゾール誘導体
|
|
JP2808460B2
(ja)
|
1989-11-16 |
1998-10-08 |
大正製薬株式会社 |
イミダゾール誘導体
|
|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
|
US5717100A
(en)
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
|
GB2306108A
(en)
|
1995-10-13 |
1997-04-30 |
Merck & Co Inc |
Treatment of Raf-mediated cancers with imidazole derivatives
|
|
US6268308B1
(en)
|
1996-08-27 |
2001-07-31 |
Syngenta Crop Protection, Inc. |
Herbicidal S-substituted 1,2,4,6-thiatriazines
|
|
NZ510991A
(en)
|
1997-03-05 |
2002-11-26 |
Sugen Inc |
Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
GB9711650D0
(en)
|
1997-06-05 |
1997-07-30 |
Pfizer Ltd |
Compounds useful in therapy
|
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
|
JP2002541253A
(ja)
|
1999-04-09 |
2002-12-03 |
スミスクライン・ビーチャム・コーポレイション |
トリアリールイミダゾール
|
|
NZ513639A
(en)
|
1999-04-15 |
2004-02-27 |
Bristol Myers Squibb Co |
Cyclic protein tyrosine kinase inhibitors
|
|
JP2000302680A
(ja)
|
1999-04-23 |
2000-10-31 |
Takeda Chem Ind Ltd |
脳保護剤
|
|
EP1218358B1
(en)
|
1999-09-23 |
2006-09-13 |
AstraZeneca AB |
Therapeutic quinazoline compounds
|
|
US7189745B1
(en)
|
1999-11-22 |
2007-03-13 |
Smithkline Beecham Corporation |
Compounds
|
|
AU782883B2
(en)
|
2000-01-18 |
2005-09-08 |
Vertex Pharmaceuticals Incorpoated |
Gyrase inhibitors and uses thereof
|
|
EP1251849A1
(en)
|
2000-01-18 |
2002-10-30 |
Vertex Pharmaceuticals Incorporated |
Gyrase inhibitors and uses thereof
|
|
CO5271680A1
(es)
|
2000-02-21 |
2003-04-30 |
Smithkline Beecham Corp |
Compuestos
|
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
DE60103136T2
(de)
|
2000-03-06 |
2004-10-28 |
Smithkline Beecham Plc, Brentford |
Imidazolderivate als Raf-Kinase Inhibitoren
|
|
GB0007405D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Corp |
Compounds
|
|
EP1268474A2
(en)
|
2000-03-30 |
2003-01-02 |
Takeda Chemical Industries, Ltd. |
Substituted 1,3-thiazole compounds, their production and use
|
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
|
PT1300396E
(pt)
|
2000-06-12 |
2009-04-20 |
Eisai R&D Man Co Ltd |
Compostos de 1,2-di-hidropiridina, processos para a sua preparação e sua utilização
|
|
WO2002006213A2
(en)
|
2000-07-19 |
2002-01-24 |
Warner-Lambert Company |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
CA2428191A1
(en)
|
2000-11-07 |
2002-05-30 |
Bristol-Myers Squibb Company |
Acid derivatives useful as serine protease inhibitors
|
|
WO2002039954A2
(en)
|
2000-11-20 |
2002-05-23 |
Smithkline Beecham Corporation |
Novel compounds
|
|
AU2002232439A1
(en)
|
2000-11-29 |
2002-06-11 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
|
DE60215139T2
(de)
|
2001-01-26 |
2007-08-16 |
Chugai Seiyaku K.K. |
Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
|
|
EP1364949A4
(en)
|
2001-02-02 |
2005-11-23 |
Takeda Pharmaceutical |
JNK INHIBITOR
|
|
US20030009034A1
(en)
|
2001-03-22 |
2003-01-09 |
Neil Wishart |
Transition metal mediated process
|
|
JP2002338537A
(ja)
|
2001-05-16 |
2002-11-27 |
Mitsubishi Pharma Corp |
アミド化合物およびその医薬用途
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
GB0129260D0
(en)
|
2001-12-06 |
2002-01-23 |
Eisai London Res Lab Ltd |
Pharmaceutical compositions and their uses
|
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
ATE447404T1
(de)
|
2002-03-29 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
|
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
|
MXPA05002332A
(es)
|
2002-09-18 |
2005-06-08 |
Pfizer Prod Inc |
Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf).
|
|
KR20050057392A
(ko)
|
2002-09-18 |
2005-06-16 |
화이자 프로덕츠 인크. |
전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물
|
|
US7531553B2
(en)
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
|
JP4758349B2
(ja)
|
2003-10-08 |
2011-08-24 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
タンパク質キナーゼ阻害剤としての化合物および組成物
|
|
JP4755991B2
(ja)
|
2003-10-16 |
2011-08-24 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
|
|
DK1692113T3
(en)
|
2003-11-14 |
2018-01-08 |
Lorus Therapeutics Inc |
ARYLIMIDAZOLES AND USE THEREOF AS ANTICANCES
|
|
US7678810B2
(en)
|
2004-03-05 |
2010-03-16 |
Taisho Pharmaceutical Co., Ltd |
Thiazole derivative
|
|
KR100749566B1
(ko)
|
2004-04-21 |
2007-08-16 |
이화여자대학교 산학협력단 |
Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
|
|
WO2005105814A1
(en)
|
2004-04-28 |
2005-11-10 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
|
PT2298768E
(pt)
|
2004-06-11 |
2012-12-05 |
Japan Tobacco Inc |
Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
|
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415367D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
EP1786802A1
(en)
|
2004-08-31 |
2007-05-23 |
Biogen Idec MA, Inc. |
Pyrimidinylimidazoles as tgf-beta inhibitors
|
|
WO2006038734A1
(en)
|
2004-10-08 |
2006-04-13 |
Astellas Pharma Inc. |
Pyridazinone derivatives cytokines inhibitors
|
|
AU2005295734A1
(en)
|
2004-10-15 |
2006-04-27 |
Biogen Idec Ma Inc. |
Methods of treating vascular injuries
|
|
JP2007246520A
(ja)
|
2006-02-15 |
2007-09-27 |
Takeda Yuichiro |
Ｒａｇｅ阻害剤
|
|
EP2007393B1
(en)
|
2006-04-07 |
2013-08-21 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
|
|
US8022205B2
(en)
|
2006-08-08 |
2011-09-20 |
Chugai Seiyaku Kabushiki Kaisha |
Pyrimidine derivatives as PI3K inhibitor and use thereof
|
|
WO2008071605A2
(en)
|
2006-12-15 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
RU2479580C2
(ru)
|
2007-06-27 |
2013-04-20 |
Астразенека Аб |
Производные пиразинона и их применение для лечения легочных заболеваний
|
|
CL2008001933A1
(es)
|
2007-06-29 |
2009-09-25 |
Millennium Pharm Inc |
Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
|
|
NZ582349A
(en)
|
2007-06-29 |
2012-06-29 |
Sunesis Pharmaceuticals Inc |
Heterocyclic compounds useful as raf kinase inhibitors
|
|
WO2009003998A2
(en)
|
2007-07-02 |
2009-01-08 |
Boehringer Ingelheim International Gmbh |
Antiproliferative compounds based on 5-membered heterocycles
|
|
EP2178866A2
(en)
|
2007-07-09 |
2010-04-28 |
AstraZeneca AB |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
US20100190777A1
(en)
|
2007-07-17 |
2010-07-29 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
WO2009014637A2
(en)
|
2007-07-19 |
2009-01-29 |
Schering Corporation |
Heterocyclic amide compounds as protein kinase inhibitors
|
|
US20110190280A1
(en)
|
2007-08-29 |
2011-08-04 |
George Adjabeng |
Thiazole And Oxazole Kinase Inhibitors
|
|
UY31322A1
(es)
|
2007-09-05 |
2009-04-30 |
|
Amidas heterocíclicas y sus métodos de uso-975
|
|
WO2009047163A1
(en)
|
2007-10-10 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
TW200940537A
(en)
|
2008-02-26 |
2009-10-01 |
Astrazeneca Ab |
Heterocyclic urea derivatives and methods of use thereof
|
|
BRPI0908906A2
(pt)
|
2008-03-21 |
2019-09-24 |
Novartis Ag |
compostos heterocíclicos e usos dos mesmos
|
|
US8865732B2
(en)
|
2008-03-21 |
2014-10-21 |
Novartis Ag |
Heterocyclic compounds and uses thereof
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
EP2297097A2
(en)
|
2008-06-11 |
2011-03-23 |
Irm Llc |
Compounds and compositions useful for the treatment of malaria
|
|
PL2324008T3
(pl)
|
2008-07-24 |
2012-09-28 |
Nerviano Medical Sciences Srl |
3,4-diarylopirazole jako inhibitory kinazy białkowej
|
|
EA019094B1
(ru)
|
2008-08-22 |
2014-01-30 |
Новартис Аг |
Пирролопиримидины и их применение
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
BRPI0924084B1
(pt)
|
2008-12-19 |
2021-12-21 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina e composição farmacêutica que os compreende
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
WO2011026911A1
(en)
|
2009-09-04 |
2011-03-10 |
Novartis Ag |
Bipyridines useful for the treatment of proliferative diseases
|
|
WO2011059610A1
(en)
|
2009-11-10 |
2011-05-19 |
Glaxosmithkline Llc |
Benzene sulfonamide thiazole and oxazole compounds
|
|
WO2011081205A1
(ja)
|
2009-12-28 |
2011-07-07 |
一般社団法人ファルマＩｐ |
１，３，４－オキサジアゾール－２－カルボキサミド化合物
|
|
US9315491B2
(en)
|
2009-12-28 |
2016-04-19 |
Development Center For Biotechnology |
Pyrimidine compounds as mTOR and PI3K inhibitors
|
|
KR20110123657A
(ko)
|
2010-05-07 |
2011-11-15 |
에스케이케미칼주식회사 |
피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
|
|
KR20130048293A
(ko)
|
2010-06-25 |
2013-05-09 |
노파르티스 아게 |
단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
|
|
EP2608790A4
(en)
|
2010-08-26 |
2014-04-02 |
Glaxosmithkline Llc |
PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
|
|
CN101993415B
(zh)
|
2010-09-15 |
2013-08-14 |
北京韩美药品有限公司 |
作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
|
|
US20120115878A1
(en)
|
2010-11-10 |
2012-05-10 |
John Vincent Calienni |
Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
|
|
MA34948B1
(fr)
|
2011-02-07 |
2014-03-01 |
Plexxikon Inc |
Composes et procedes de modulation de kinase, et leurs indications
|
|
WO2013022766A1
(en)
|
2011-08-05 |
2013-02-14 |
Flynn Gary A |
Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
|
|
WO2013033167A1
(en)
|
2011-09-01 |
2013-03-07 |
Irm Llc |
Compounds and compositions as c-kit kinase inhibitors
|
|
CA2849189A1
(en)
|
2011-09-21 |
2013-03-28 |
Cellzome Limited |
Morpholino substituted urea or carbamate derivatives as mtor inhibitors
|
|
US9399638B2
(en)
|
2012-05-02 |
2016-07-26 |
Lupin Limited |
Substituted pyridine compounds as CRAC modulators
|
|
US9278981B2
(en)
|
2012-05-15 |
2016-03-08 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
|
WO2014008214A1
(en)
|
2012-07-02 |
2014-01-09 |
Biogen Idec Ma Inc. |
Biaryl-containing compounds as inverse agonists of ror-gamma receptors
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
JP6342396B2
(ja)
*
|
2012-08-07 |
2018-06-13 |
ノバルティス アーゲー |
Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
|
|
HRP20211817T1
(hr)
|
2012-09-04 |
2022-03-04 |
Novartis Ag |
Postupak adjuvantnog liječenja raka
|
|
EA030253B1
(ru)
|
2012-09-28 |
2018-07-31 |
Кэнсэр Ресерч Текнолоджи Лимитед |
Азахиназолиновые ингибиторы атипичной протеинкиназы c
|
|
US9586948B2
(en)
|
2012-10-08 |
2017-03-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of IRAK4 activity
|
|
WO2014097125A1
(en)
*
|
2012-12-20 |
2014-06-26 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
US9242969B2
(en)
*
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
DK2976106T3
(da)
*
|
2013-03-21 |
2021-06-14 |
Array Biopharma Inc |
Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
|
|
LT3063143T
(lt)
*
|
2013-11-01 |
2018-08-10 |
Novartis Ag |
Aminoheteroarilbenzamidai, kaip kinazės inhibitoriai
|
|
AU2014368906B2
(en)
*
|
2013-12-20 |
2020-04-30 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of ERK and RAF inhibitors
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
WO2016038583A1
(en)
|
2014-09-12 |
2016-03-17 |
Novartis Ag |
Compounds and compositions as kinase inhibitors
|
|
WO2016038582A1
(en)
|
2014-09-12 |
2016-03-17 |
Novartis Ag |
Compounds and compositions as raf kinase inhibitors
|
|
WO2016115376A1
(en)
*
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Of California |
Detection and treatment of double drug resistant melanomas
|
|
CA2991805A1
(en)
|
2015-07-10 |
2017-01-19 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
US10328066B2
(en)
*
|
2015-08-28 |
2019-06-25 |
Novartis Ag |
Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
|
EP3340987A1
(en)
|
2015-08-28 |
2018-07-04 |
Novartis AG |
Combination of ribociclib and dabrafenib for treating or preventing cancer
|
|
BR112018074941A2
(pt)
*
|
2016-06-03 |
2019-03-12 |
Caponigro Giordano |
combinações farmacêuticas
|
|
CA3026876A1
(en)
*
|
2016-06-10 |
2017-12-14 |
Novartis Ag |
Therapeutic uses of a c-raf inhibitor
|
|
EP3515446B1
(en)
|
2016-09-19 |
2023-12-20 |
Novartis AG |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
US11590133B2
(en)
|
2016-12-11 |
2023-02-28 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for treatment of BRAF mutant cancers
|
|
US11266653B2
(en)
|
2017-05-02 |
2022-03-08 |
Novartis Ag |
Combination therapy
|
|
JP7405408B2
(ja)
|
2017-05-16 |
2023-12-26 |
バイオメッド バレー ディスカバリーズ，インコーポレイティド |
異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
|
|
WO2020046966A1
(en)
|
2018-08-27 |
2020-03-05 |
Kura Oncology, Inc. |
Treatment of adenocarcinomas with mapk pathway inhibitors
|
|
CN113453671A
(zh)
|
2018-12-20 |
2021-09-28 |
诺华股份有限公司 |
用于治疗癌症的Raf抑制剂和CDK4/6抑制剂的组合疗法
|
|
ES3025633T3
(en)
|
2019-05-13 |
2025-06-09 |
Novartis Ag |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
US20230226030A1
(en)
|
2020-02-18 |
2023-07-20 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
|
|
WO2021229439A1
(en)
|
2020-05-12 |
2021-11-18 |
Novartis Ag |
Therapeutic combinations comprising a craf inhibitor
|